Unicycive Therapeutics, Inc. (UNCY) 10-Year Financial Performance & Capital Metrics

UNCY • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

AboutUnicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.Show more

Revenue $0 -100.0%
EBITDA -$32M -54.7%
Net Income -$37M -20.2%
EPS (Diluted) -5.60 -337.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -2028.11%
ROIC -
Debt/Equity 0.10
Interest Coverage -452.35 -78.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Healthy dividend yield of 2.6%

✗Weaknesses

✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-45.26%

EPS CAGR

10Y-

5Y-

3Y-

TTM50.92%

ROCE

10Y Avg-626.45%

5Y Avg-626.45%

3Y Avg-875.4%

Latest-1527.56%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	951K	675K	0
Revenue Growth %	-	-	-	-	-	-0.29%	-1%
Cost of Goods Sold+	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	951K	675K	0
Gross Margin %	-	-	-	-	1%	1%	-
Gross Profit Growth %	-	-	-	-	-	-0.29%	-1%
Operating Expenses+	952K	1.96M	2.02M	8.98M	19M	21.45M	32.12M
OpEx % of Revenue	-	-	-	-	19.98%	31.78%	-
Selling, General & Admin	608K	1.17M	1M	2.9M	6.57M	8.55M	12.1M
SG&A % of Revenue	-	-	-	-	6.91%	12.66%	-
Research & Development	344K	795K	1.01M	6.08M	12.44M	12.9M	20.01M
R&D % of Revenue	-	-	-	-	13.08%	19.11%	-
Other Operating Expenses	0	0	0	0	0	0	0
Operating Income+	-952K	-1.96M	-2.02M	-8.98M	-18.05M	-20.77M	-32.12M
Operating Margin %	-	-	-	-	-18.98%	-30.78%	-
Operating Income Growth %	-	-1.06%	-0.03%	-3.44%	-1.01%	-0.15%	-0.55%
EBITDA+	0	0	0	-8.96M	-17.89M	-20.49M	-31.69M
EBITDA Margin %	-	-	-	-	-18.81%	-30.36%	-
EBITDA Growth %	-	-	-	-	-1%	-0.15%	-0.55%
D&A (Non-Cash Add-back)	952K	1.96M	2.02M	13K	161K	284K	428K
EBIT	-952K	-2.03M	-2.02M	-9.39M	-18.05M	-30.46M	-36.66M
Net Interest Income+	0	0	0	-628K	-6K	533K	1.19M
Interest Income	168K	139K	244K	0	0	615K	1.26M
Interest Expense	0	139K	244K	628K	6K	82K	71K
Other Income/Expense	-168K	-202K	-244K	-1.04M	-6K	-9.77M	-4.61M
Pretax Income+	-1.12M	-2.17M	-2.26M	-10.02M	-18.06M	-30.54M	-36.73M
Pretax Margin %	-	-	-	-	-18.99%	-45.25%	-
Income Tax+	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1.06%	1.11%	1%	1%	1%	1%
Net Income+	-1.12M	-2.3M	-2.51M	-10.02M	-18.06M	-30.54M	-36.73M
Net Margin %	-	-	-	-	-18.99%	-45.25%	-
Net Income Growth %	-	-1.06%	-0.09%	-2.99%	-0.8%	-0.69%	-0.2%
Net Income (Continuing)	-1.12M	-2.17M	-2.26M	-10.02M	-18.06M	-30.54M	-36.73M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.14	-0.27	-0.16	-8.60	-1.20	-1.28	-5.60
EPS Growth %	-	-0.93%	0.41%	-52.75%	0.86%	-0.07%	-3.38%
EPS (Basic)	-0.14	-0.27	-0.16	-8.60	-1.20	-1.28	-5.60
Diluted Shares Outstanding	794.32K	847.15K	1.52M	1.17M	1.51M	2.45M	6.7M
Basic Shares Outstanding	794.32K	842.5K	1.52M	1.17M	1.51M	2.45M	6.7M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	29K	19K	204K	18.41M	2.64M	13.4M	30.95M
Cash & Short-Term Investments	25K	15K	0	16.58M	455K	9.7M	26.14M
Cash Only	25K	15K	0	16.58M	455K	9.7M	26.14M
Short-Term Investments	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	4K	204K	126K	159K	325K	939K
Total Non-Current Assets+	0	0	200K	333K	174K	792K	720K
Property, Plant & Equipment	0	0	0	333K	174K	792K	720K
Fixed Asset Turnover	-	-	-	-	5.47x	0.85x	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	200K	0	0	0	0
Total Assets+	29K	19K	204K	18.74M	2.82M	14.19M	31.67M
Asset Turnover	-	-	-	-	0.34x	0.05x	-
Asset Growth %	-	-0.34%	9.74%	90.88%	-0.85%	4.04%	1.23%
Total Current Liabilities+	1.24M	903K	2.88M	2.1M	3.28M	17.53M	24.12M
Accounts Payable	60K	322K	184K	742K	846K	821K	966K
Days Payables Outstanding	-	-	-	-	-	-	-
Short-Term Debt	1.05M	460K	2.51M	29K	46K	18K	92K
Deferred Revenue (Current)	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	-29K	0	13.13M	18.94M
Current Ratio	0.02x	0.02x	0.07x	8.75x	0.81x	0.76x	1.28x
Quick Ratio	0.02x	0.02x	0.07x	8.75x	0.81x	0.76x	1.28x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	155K	0	466K	117K
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	155K	0	466K	117K
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0
Total Liabilities	1.24M	903K	2.88M	2.26M	3.28M	18M	24.24M
Total Debt+	1.05M	460K	2.51M	335K	201K	811K	773K
Net Debt	1.02M	445K	2.51M	-16.24M	-254K	-8.89M	-25.37M
Debt / Equity	-	-	-	0.02x	-	-	0.10x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-14.12x	-8.28x	-14.29x	-3008.67x	-253.34x	-452.35x
Total Equity+	-1.21M	-884K	-2.67M	16.48M	-466K	-3.81M	7.43M
Equity Growth %	-	0.27%	-2.02%	7.17%	-1.03%	-7.17%	2.95%
Book Value per Share	-1.52	-1.04	-1.75	14.12	-0.31	-1.55	1.11
Total Shareholders' Equity	-1.21M	-884K	-2.67M	16.48M	-466K	-3.81M	7.43M
Common Stock	34K	8K	9K	15K	15K	35K	114K
Retained Earnings	-1.49M	-3.66M	-5.92M	-15.94M	-34M	-64.54M	-101.27M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-775K	-1.18M	-1.46M	-5.77M	-15.65M	-18.28M	-28.57M
Operating CF Margin %	-	-	-	-	-16.46%	-27.09%	-
Operating CF Growth %	-	-0.52%	-0.24%	-2.95%	-1.71%	-0.17%	-0.56%
Net Income	-1.12M	-2.17M	-2.26M	-10.02M	-18.06M	-30.54M	-36.73M
Depreciation & Amortization	0	0	0	13K	161K	284K	428K
Stock-Based Compensation	0	24K	232K	966K	1.05M	1.77M	2.35M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	308K	660K	739K	3.38M	21K	10.3M	5.8M
Working Capital Changes	6K	305K	-166K	-105K	1.18M	-93K	-427K
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	31K	308K	-68K	1.24M	1.27M	1.28M	790K
Cash from Investing+	0	0	0	-29K	-2K	-12K	-72K
Capital Expenditures	0	0	0	-29K	-2K	-12K	-72K
CapEx % of Revenue	-	-	-	-	0%	0.02%	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0
Cash from Financing+	800K	1.17M	1.44M	22.38M	-471K	27.54M	45.09M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	-1.09M
Share Repurchases	-	-	-	-	-	-	-
Other Financing	800K	0	-117K	119K	-482K	-2.65M	-4.5M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-775K	-1.18M	-1.46M	-5.8M	-15.65M	-18.3M	-28.65M
FCF Margin %	-	-	-	-	-16.46%	-27.1%	-
FCF Growth %	-	-0.52%	-0.24%	-2.97%	-1.7%	-0.17%	-0.57%
FCF per Share	-0.98	-1.39	-0.96	-4.96	-10.40	-7.46	-4.28
FCF Conversion (FCF/Net Income)	0.69x	0.51x	0.58x	0.58x	0.87x	0.60x	0.78x
Interest Paid	0	0	0	0	0	24K	0
Taxes Paid	0	2K	1K	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-145.04%	-225.47%	-	-2028.11%
Return on Invested Capital (ROIC)	-	-	-	-16223.49%	-	-	-
Gross Margin	-	-	-	-	100%	100%	-
Net Margin	-	-	-	-	-1898.84%	-4525.04%	-
Debt / Equity	-	-	-	0.02x	-	-	0.10x
Interest Coverage	-	-14.12x	-8.28x	-14.29x	-3008.67x	-253.34x	-452.35x
FCF Conversion	0.69x	0.51x	0.58x	0.58x	0.87x	0.60x	0.78x
Revenue Growth	-	-	-	-	-	-29.02%	-100%

Frequently Asked Questions

Growth & Financials

Unicycive Therapeutics, Inc. (UNCY) saw revenue decline by 100.0% over the past year.

Unicycive Therapeutics, Inc. (UNCY) reported a net loss of $33.4M for fiscal year 2024.

Dividend & Returns

Yes, Unicycive Therapeutics, Inc. (UNCY) pays a dividend with a yield of 2.61%. This makes it attractive for income-focused investors.

Unicycive Therapeutics, Inc. (UNCY) has a return on equity (ROE) of -2028.1%. Negative ROE indicates the company is unprofitable.

Unicycive Therapeutics, Inc. (UNCY) had negative free cash flow of $29.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener